Navigation Links
Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies
Date:1/13/2012

CHAPEL HILL, N.C., Jan. 13, 2012 /PRNewswire/ -- Bio-Pharmaceutical and medical device leaders are re-evaluating their staffing and investment levels in light of increasing regulatory and market pressures in the U.S., according to analysts at research and consulting firm Best Practices, LLC.

To identify which resourcing strategies will best reduce risk and enhance growth in the quickly changing healthcare industry, Best Practices, LLC, a world-leader in biopharmaceutical benchmarking and best practice research, has launched a new study: "Public Affairs and Public Policy Staffing in the U.S. Marketplace for Biopharmaceutical and Medical Device Companies."

This landmark study comprises wide-ranging staffing investment insights from bio-pharma and medical device executives across areas such as Structure and Reporting Relationships, Staffing and Investment and Consolidated Staffing and Investment Efficiency Ratios for the following functions:

  • Government Affairs (State and Federal Government Relations and Public Policy)
  • Corporate Communications – External
  • Corporate Communication – Internal
  • Product Communications
  • Corporate Social Responsibility
  • Alliance Management

This critical research study represents the latest contribution of Best Practices, LLC to the life science industry's staffing and investment knowledge.  While previous studies have captured key metrics to identify optimal resource levels for maximum competitiveness, regulatory and other changes have continued to erode the effectiveness of the industry's proven business model -  a fact pressing executives to reconsider efficient levels of human and capital investment.

This latest study therefore offers an open benchmark opportunity for public affairs/public policy executives throughout the bio-pharma and medical device sectors.

For assistance or questions related to this study, contact research team leader Cameron Tew at ctew@best-in-class.com or (919) 767-9246. Responses are requested by Feb. 21, 2012.

There is no cost to participate, and all benchmark participants will receive the complete, blinded research results and analysis for free. This study will generate comparative metrics and executive insights that participants can use in the future to help assess what staffing and investment levels are right for different sizes of company.

All responses are blinded and aggregated to protect confidentiality. To view or participate in the online survey, follow this link: http://app.sgizmo.com/preview_survey.php?id=91334&k=I1283c7fxPu28NtobvbYNIfk4eEhy0&u=pwalve%40best-in-class%2ecom

BEST PRACTICES, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.

The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BNA Books Announces the Publication of the 2011 Cumulative Supplement to "Pharmaceutical Law: Regulation of Research, Development, and Marketing"
2. Radient Pharmaceuticals Announces New Advertisement for Oncology Publications
3. Successful Diabetes Product Launches Balance Digital & Traditional Public Relations Tools
4. OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
5. BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition"
6. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
7. Ampio Responds to Recent Publications by Anonymous Short Sellers
8. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
9. Utilizing Public Relation Strategies During Pharmaceutical Lifecycle Management for Greatest Impact on Brand and Consumer Base
10. Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nations Public and Private Health Testing
11. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):